On average, more than 70% of the drugs found in PDR have updated prescribing information from that found in the previous year's edition. This means that each year thousands of changes are made to:Interactions with other drugsContraindicationsSide EffectsBlack box warningsRecommended dosagesHow-supplied methodsWith the new 2004 PDR, you'll find the most complete, up-to-date information on over 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product categories plus more than 2,000 full-size, full-color photos cross referenced to the drug. You'll also find information on the latest drugs approved by the FDA including:Zetia (ezetimibe), the first in a new class of lipid-lowering agents.Strattera (atomoxetine HCl), the first selective norepinephrine reuptake inhibitor for treatment of attention-deficit/hyperactivity disorder.Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B [recombinant] and inactivated poliovirus vaccine combined), the five-in-one vaccine/toxoid combination indicated as a 3-dose primary series for active immunization against diphtheria, tetanus, pertussis, hepatitis B, and polio. Forteo (teriparatide[rDNA origin]), a new recombinant human parathyroid hormone for treatment of postmenopausal women with osteoporosis, and to increase bone mass in men with primary or hypogonadal osteoporosis. Humira (adalimumab), a new recombinant human monoclonal antibody for rheumatoid arthritis. Cipro XR (ciprofloxacin), a new extended-release fluoroquinolone for treatment of uncomplicated urinary tract infections. Amevive (alefacept), an immunosuppressive agent for treatment of moderate to severe chronic plaque psoriasis.